Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00730314
Other study ID # CCI #07-00119
Secondary ID CHLA-#07-00119
Status Completed
Phase Phase 1/Phase 2
First received August 6, 2008
Last updated June 21, 2016
Start date August 2008
Est. completion date August 2015

Study information

Verified date June 2016
Source Children's Hospital Los Angeles
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This is a clinical trial of bone marrow transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor. Genetic diseases of blood cell include: Red blood cell defects e.g. hemoglobinopathies (sickle cell disease and thalassemia), Blackfan-Diamond anemia and congenital or chronic hemolytic anemias; White blood cells defects/immune deficiencies e.g. chronic granulomatous disease, Wiskott-Aldrich syndrome,Osteopetrosis, Kostmann's syndrome (congenital neutropenia), Hereditary Lymphohistiocytosis (HLH); Platelets defects e.g.Congenital amegakaryocytic thrombocytopenia; Metabolic/storage disorders e.g. leukodystrophies,mucopolysaccharidoses as Hurler disease;Stem cell defects e.g.reticular agenesis, among many other rare similar conditions.

The study treatment plan uses a new transplant treatment regimen that aims to try to decrease the acute toxicities and complications associated with the standard treatment plans and to improve outcome

The blood stem cells will be derived from either unrelated donor or unrelated umbilical cord blood.


Description:

This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor. The stem cells will be derived from a 1) matched unrelated donor (MUD) or 2) unrelated umbilical cord blood (UCB). Patients will receive a novel conditioning regimen with Busulfan, Cytoxan and Fludarabine (Bu/Cy/Flu) and either Alemtuzumab (Campath 1H) for recipients of a MUD or rabbit Antithymocyte Globulin (rATG) for recipients of unrelated UCB prior to hematopoietic stem cell transplant (HSCT).

It is hypothesized that reduced dosages of Cytoxan will decrease the acute toxicities associated with the standard chemotherapies of Busulfan and Cytoxan (i.e. sinusoidal obstructive syndrome (SOS), hemorrhagic cystitis and mucositis). And the addition of fludarabine to a conditioning regimen with myeloablative doses of Busulfan and reduced dosages of Cytoxan prior to HSCT will overcome the engraftment barrier posed by an intact immune system, which is seen in patients with a genetic disease.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date August 2015
Est. primary completion date August 2015
Accepts healthy volunteers No
Gender Both
Age group N/A to 21 Years
Eligibility Inclusion Criteria:

- Lethal or sublethal genetic disease of blood cells, who lack a fully histocompatible sibling or other family donor

- Genetic diseases that would be candidates for this protocol includes those that have been shown to benefit from allogeneic HSCT: Red blood cell defects, Leukocyte defects/ Primary immune deficiencies, Platelets defects, Metabolic/storage disorders and Stem cell defects.

- Renal: creatinine clearance or glomerular filtration rate (GFR) =50 ml/min/1.73m2 and not requiring dialysis.

- Pulmonary: FEV1, FVC and DLCO (corrected for hemoglobin) = 50% predicted. if unable to perform pulmonary function tests, then O2 saturation = 92% in room air.

- Cardiac: Left ventricular ejection fraction at rest must be = 40%, or shortening fraction = 26%

- Hepatic: Bilirubin =3x upper limit of normal (ULN) and ALT and AST = 5x for age (with the exception of isolated hyperbilirubinemia due to Gilbert's syndrome).

- Patients will be 0-21 years of age.

- Disease specific inclusion criteria (as applicable per protocol).

Exclusion Criteria:

- Recipients should not have any of the general exclusion criteria, and disease specific exclusion criteria when applicable.

- Patient with histocompatible sibling

- End-organ failure that precludes the ability to tolerate the transplant procedure, including the conditioning regimen.

- Creatinine clearance or GFR < 50 ml/min/1.73m2 or renal failure requiring dialysis.

- Congenital heart disease resulting in congestive heart failure.

- Severe residual CNS disease/impairment [(other than hemiplegia alone) e.g. coma or intractable seizures]

- Ventilatory failure

- Major congenital anomalies that adversely affect survival, e.g. CNS malformations

- Lansky score < 40% or Karnofsky score < 60%

- HIV seropositivity

- Diagnosis of Fanconi's anemia, Severe Combined Immunodeficiency (SCID)

- Positive pregnancy test (For female patients in child bearing period)

- Uncontrolled bacterial, viral, or fungal infections (currently taking medication yet clinical symptoms progress)

- Disease specific exclusion criteria (as applicable per protocol).

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Procedure:
Hematopoietic stem cell transplantation
hematopoietic stem cell transplantation conditioning regimen depending on graft source

Locations

Country Name City State
United States Children Hospital Los Angeles Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Children's Hospital Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary toxicities 3 years Yes
Primary adverse events 3 years Yes
Primary engraftment 1 year Yes
Primary immune reconstitution 3 years Yes
Primary overall and event free survival survival 3 years Yes
See also
  Status Clinical Trial Phase
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT03341338 - Genes-in-Action - Hepcidin Regulation of Iron Supplementation
Completed NCT00060398 - Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Not yet recruiting NCT06309641 - Methemoglobinemia Following Intravenous Iron Treatment
Completed NCT02912533 - A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02930850 - Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation N/A
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02912494 - A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT03822884 - Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers Phase 1
Completed NCT02603250 - Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda N/A
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Completed NCT01922479 - Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure Phase 4
Withdrawn NCT01934842 - A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate N/A
Completed NCT02310113 - Transfusion and Skeletal Muscle Tissue Oxygenation N/A
Completed NCT01693029 - Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Phase 3
Completed NCT01432717 - Study of ACE-536 in Healthy Postmenopausal Women Phase 1
Terminated NCT01535781 - Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced? N/A

External Links